Design Therapeutics Inc Aktie News

Änderungen an der RESTORE‑FA‑Studie bauen auf positiven Daten nach vier Wochen auf; Erwartung, Daten basierend auf 12 Wochen Dosierung im ersten Quartal 2027 zu veröffentlichen Patientenaufdosierung in Phase‑1‑Mehrfach‑Aufsteigerdosis‑Studie von DT‑818 bei Myotonic‑Dystrophie‑Typ‑1 begonnen Zahlungsmittel und Wertpapiere in Höhe von 207,4 Mio. USD zum Quartalsende bieten starke finanzielle Lauf...

GeneTAC®‑Kleinmolekül, entwickelt, um selektiv die Transkription des mutanten DMPK‑Allels zu reduzieren und die zugrundeliegende Ursache von DM1 anzugehen CARLSBAD, Calif., 30. Juni 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), ein biotechnologisches Unternehmen im klinischen Stadium, das Behandlungen für schwere degenerative genetische Erkrankungen entwickelt, gab heute de...

CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m.

Design Therapeutics shares ran up early Monday on positive results in Friedreich's ataxia. And then, the biotech stock lost it all.

DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing

CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast...

Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and Securities of $222.8 Million at Quarter-End Provide Runway to Support Ongoing Clinical Execution CARLSBAD, Calif.